Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

About Erone Technologies

Developer of therapies for difficult-to-treat and drug-resistant infectious diseases. The company develops a novel FGF-induced immediate-early gene, ER1. The company's research is based on belief that inhibition of the expression or activity of ER1 may inhibit the proliferation and tumorigenic properties of certain cancer cell lines, such as breast and melanoma.

Erone Technologies Headquarter Location

University of Newfoundland / Dr. Paterno 300 Prince Phillip Drive

St. John's, Newfoundland and Labrador, A1B 3V6,

Canada

(709)777-7012

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.